Cases & Deals

GE Healthcare acquires Rapidscan

Clients General Electric Company

Jones Day advised GE Healthcare in connection with its acquisition of Rapidscan Pharma Solutions, Inc., which is a single product pharmaceutical company with the exclusive rights to produce and sell the pharmacological stress agent Rapiscan® (regadenoson) in territories outside of North America.  Rapiscan® is a European Medicines Agency (EMA) approved selective coronary vasodilator, used as a pharmacological stress agent for radionuclide myocardial perfusion imaging (MPI) in adult patients. It is used in the diagnosis of coronary artery disease (CAD), the most common type of cardiovascular disease.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.